DrugBiological
Tertomotide clinical trials
Also written GV1001.
- studies test it
- 14
- open now
- 1
- in phase 3
- 4
- first study started
- 2005
Keep track of what changes. Save the tertomotide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
13 studies that test it; most in 2006 (3); 1 more planned to start later
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 3 |
| 2012 | 1 |
| 2015 | 2 |
| 2017 | 1 |
| 2019 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 8
- Phase 3
- 4
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 2
GemVax & Kael (7) · Oslo University Hospital (2) · Pharmexa A/S (2) · Samsung Pharmaceutical Co., Ltd. (2) · Kael-GemVax Co., Ltd. (1)
Studies
Open first, then newest update. How each study uses tertomotide is read from its arms, and is right about nine times in ten.
Testing it · 14
- GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD)Not yet recruitingPhase 3Samsung Pharmaceutical Co., Ltd.NCT05303701Written as GV1001 1.12mg
- GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP)CompletedPhase 2GemVax & KaelNCT05819658Written as GV1001 0.56mg
- Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011CompletedPhase 2GemVax & KaelNCT06235775Written as GV1001 1.12mg
- Evaluation of the Safety, Tolerability and PK Characteristics of GV1001 in Healthy SubjectsCompletedPhase 1GemVax & KaelNCT06625710Written as GV1001
- GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)CompletedPhase 2GemVax & KaelNCT05189210Written as GV1001 0.56mg
- A Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With BPHCompletedPhase 2GemVax & KaelNCT02855892Written as GV1001
- GV1001 Subcutaneous(SC) for the Treatment of Moderate Alzheimer's Disease (AD)WithdrawnPhase 2GemVax & KaelNCT03959553Written as GV1001
- Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer PatientsCompletedPhase 2GemVax & KaelNCT03184467Written as GV1001 0.56 mg
- A Phase III Study to Assess the Efficacy and Safety of GV1001-Gem/Cap vs Gem/Cap in Pancreatic Cancer PatientsStatus unknownPhase 3Samsung Pharmaceutical Co., Ltd.NCT02854072Written as GV1001
- Trial With Telomerase Peptide Vaccine In Combination With Temozolomide in Patients With Advanced Malignant MelanomaCompletedPhase 1/2Oslo University HospitalNCT01247623Written as GV1001
- Study of the Telomerase Vaccine GV1001 to Treat Patients With Inoperable Stage III Non-small Cell Lung CancerStatus unknownPhase 3Kael-GemVax Co., Ltd.NCT01579188Written as GV1001
- GV 1001 Immunotherapy in Patients With Non-small Cell Lung Cancer (NSCLC)CompletedNot applicableOslo University HospitalNCT00509457Written as GV 1001 Telomerase peptide
- A Phase II, Open-Label Trial Evaluating GV1001 in Advanced Hepatocellular Carcinoma.CompletedPhase 2Pharmexa A/SNCT00444782Written as GV1001
- GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Pancreatic CancerTerminatedPhase 3Pharmexa A/SNCT00358566Written as GV1001
Codes
What other systems call tertomotide · ClinicalTrials.gg INT015007
- UNII (FDA) 55R7RG342OTERTOMOTIDEOne source FDA
- NCI Thesaurus C62756TertomotideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 55R7RG342O | TERTOMOTIDE | One source FDA |
| NCI Thesaurus | C62756 | Tertomotide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.